During the past decade, great efforts have been dedicated to the development of clinically relevant interventions that would trigger potent (and hence potentially curative) anticancer immune responses. Indeed, developing
neoplasms normally establish local and systemic immunosuppressive networks that inhibit
tumor-targeting immune effector cells, be them natural or elicited by (immuno)
therapy. One possible approach to boost anticancer immunity consists in the (generally systemic) administration of recombinant immunostimulatory
cytokines. In a limited number of oncological indications, immunostimulatory
cytokines mediate clinical activity as standalone immunotherapeutic interventions. Most often, however, immunostimulatory
cytokines are employed as
immunological adjuvants, i.e., to unleash the immunogenic potential of other immunotherapeutic agents, like
tumor-targeting
vaccines and checkpoint blockers. Here, we discuss recent preclinical and clinical advances in the use of some
cytokines as immunostimulatory agents in oncological indications.